Stock screenerAll disclosures →
EDGAR →
CCCC
Conviction 47HealthcareScan · Thu, Sep 24, 2026C4 Therapeutics, Inc. (CCCC) closed at $3.03 (-1.62%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 27, RS Rating 57, -35.1% from its 52-week high, +57.0% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).
CCCC$3.03-1.62%
ResistanceSupportVol 14Vol MA14 2.13M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price3.03
Change-1.62%
Gap+0.00%
Rel volume2.35×
Avg volume2.09M
Avg $ vol7.29M
SMA 203.53
SMA 503.70
SMA 2003.10
Price vs 50-18.05%
Price vs 200-2.17%
MA stackmixed
50/200 cross—
Supertrenddown · 3.58
RSI (14)27
MACD hist-0.05
MACD cross—
Stoch %K / %D16 / 13
ADX (14)21
+DI / −DI13 / 34
RSI divergence—
MACD divergence—
ATR %6.75%
ADR %5.38%
52w high4.67
52w low1.71
From 52w high-35.12%
Above 52w low+77.19%
New 52w highNo
SqueezeOff
Bollinger width29.77%
%B0.03
Donchian pos10.56%
Donchian high4.30
Donchian low2.88
AVWAP (52w high)3.83
vs AVWAP high-20.99%
AVWAP (52w low)3.46
vs AVWAP low-12.33%
OBV trendDown
Chaikin MF (20)-0.27
Today vs 20d2.35×
Avg vol (14d)2.13M
Avg vol (20d)2.09M
Avg $ vol (20d)7.29M
Market cap372.77M
RS Rating57 / 99
RS 3m (vs SPY)-35.63%
RS 6m (vs SPY)-4.18%
RS line new highNo
Trend template4/8
Technical rank38.6
1 week-11.27%
1 month-27.86%
3 months-31.14%
6 months+12.64%
1 year+16.99%
YTD+56.99%
P/E-3.55
P/B1.51
P/S10.37
P/FCF-3.75
EPS-1.27
Div yield—
ROE-42.46%
ROA-29.21%
Debt/Eq0.00
Current5.45
EV/EBITDA—
Gross margin—
Net margin-292.08%
Rev growth1.02%
EPS growth0.31%
Price target8.50
Target upside180.53%
Analyst ratingBuy
Institutional100.13%
Ent. value294.16M
Revenue6.64M
Net income-23.64M
Gross profit—
Free cash flow-99.3M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out110.57M
Employees104
ListedFri, Oct 2, 2020
Free float75.13M
Float %77.5%
Short interest37.41M
Days to cover16.7d
Short volume28.0%
Squeeze score80 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.18 vs −$0.23
Last surprise+21.7% beat
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank38.6 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance4.35
Support3.32
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Yahoo Finance · Wed, Sep 23, 2026
Congress activity
Disclosed STOCK Act trades in CCCC
No recent disclosed trades by Congress in CCCC. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in CCCC
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Adams Kendra Chief Financial Officer · Common Stock · 2026-09-18 | Exercise | 6.25K | — | 2026-09-18 | 2026-09-21 |
Adams Kendra Chief Financial Officer · Common Stock · 2026-09-18 | Tax | 2.77K | $9K | 2026-09-18 | 2026-09-21 |
REYNO LEONARD Chief Medical Officer · Common Stock · 2026-07-10 | Exercise | 15.32K | — | 2026-07-10 | 2026-07-13 |
REYNO LEONARD Chief Medical Officer · Common Stock · 2026-07-10 | Tax | 7.4K | $30K | 2026-07-10 | 2026-07-13 |
GROGAN DONNA ROY Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
Fawell Stephen Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
Cooper Ronald Harold Wilfred Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
Hoerter Steven L. Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
Hughes Owen Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
Anderson Kenneth Carl Director · Stock Option (Right to Buy) · 2026-06-24 | Grant | 62K | — | 2026-06-24 | 2026-06-26 |
SEC filings
EDGAR filings in CCCC · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.